New Drug Channels Institute Study Analyzes Globalization of Prescription Drug Distribution, Key Profit Trends
PHILADELPHIA (BUSINESS WIRE) September 23, 2014—Today the Drug Channels Institute, a leading management educator for and about the pharmaceutical industry, released its exclusive, in-depth analysis of the highly dynamic prescription drug distribution industry. “The three largest, U.S.-based wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—are all expanding significantly outside North America,” said Drug Channels Institute CEO Adam J. Fein, Ph.D., the study’s author and a widely regarded expert on pharmacy economics and the pharmaceutical supply chain.
Fein adds, “These companies are diversifying from our domestic healthcare industry and applying U.S. best practices outside North America. They are also forming new global alliances to aggregate generic drug purchasing power.”
These findings are among the many revelations and trends in Drug Channels Institute’s new 2014–15 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This comprehensive analysis of the $300 billion drug distribution industry thoroughly dissects its interactions with the U.S. healthcare system. With 83 proprietary charts, exhibits, and data tables, this new research report offers the most complete examination of the pharmaceutical distribution industry’s economics, market structure, growth rates, and profit trends. “Traditional financial metrics can mask the underlying—and growing—profitability of pharmaceutical wholesaling,” Fein reports.
The report synthesizes a wealth of statistical data, research studies, financial information, and Dr. Fein’s unique business consulting experience into a definitive, nonpartisan resource. This provocative report analyzes how wholesalers will be affected by such trends as U.S. healthcare reform, unexpected generic drug inflation, pending Medicaid reimbursement changes, pharmacy consolidation, and more. The report also reveals how wholesalers and distributors are profiting from expensive specialty medications that treat such illnesses as cancer, multiple sclerosis, and hepatitis C.
To purchase and immediately download the new report, visit http://drugchannelsinstitute.com/products/industry_report/wholesale/
About Drug Channels Institute
Drug Channels Institute, a division of Pembroke Consulting, Inc., is a leading provider of specialized management education and computer-based training for and about the pharmaceutical industry. To learn more about its products, visit http://www.drugchannelsinstitute.com/. To access Dr. Fein’s popular Drug Channels blog, visit http://www.drugchannels.net.
Pembroke Consulting, Inc.
215-523-5700 extension 14